This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stein, C. S.
Right arrow Articles by Davidson, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stein, C. S.
Right arrow Articles by Davidson, B. L.

 Previous Article  |  Next Article 

Journal of Virology, April 1999, p. 3424-3429, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Systemic and Central Nervous System Correction of Lysosomal Storage in Mucopolysaccharidosis Type VII Mice

Colleen S. Stein,1 Abdi Ghodsi,2 Todd Derksen,1 and Beverly L. Davidson1,*

Departments of Internal Medicine1 and Neurosurgery,2 University of Iowa College of Medicine, Iowa City, Iowa 52242

Received 31 August 1998/Accepted 7 December 1998

Mucopolysaccharidosis (MPS) type VII patients lack functional beta -glucuronidase, leading to systemic and central nervous system dysfunction. In this study we tested whether recombinant adenovirus that encodes beta -glucuronidase (Adbeta gluc), delivered intravenously and into the brain parenchyma of MPS type VII mice, could provide long-term transgene expression and correction of lysosomal distension. We also tested whether systemic treatment with the immunosuppressive anti-CD40 ligand antibody, MR-1, affected transgene expression. We found substantial plasma beta -glucuronidase activity for over 9 weeks after gene transfer in the MR-1- treated group, with subsequent decline in activity corresponding to a delayed anti-beta -glucuronidase antibody response. At 16 weeks, near wild-type amounts of beta -glucuronidase activity and striking reduction of lysosomal pathology were detected in livers from mice that had received either MR-1 cotreatment or control antibody. In the lung and kidney, beta -glucuronidase activity was markedly higher for the MR-1-treated group. beta -Glucuronidase activity in the brain persisted independently of MR-1 treatment. Activity was intense in the injected hemisphere and was also evident in the noninjected cortex and striatum, with dramatic improvements in storage deposits in areas of both hemispheres. These results indicate that prolonged enzyme expression from transgenes delivered to deficient liver and brain can mediate pervasive correction and illustrate the potential for gene therapy of MPS and other lysosomal storage diseases.

* Corresponding author. Mailing address: University of Iowa College of Medicine, 200 EMRB, Iowa City, IA 52242. Phone: (319) 353-5511. Fax: (319) 335-7623. E-mail: beverly-davidson{at}uiowa.edu.

Journal of Virology, April 1999, p. 3424-3429, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Akeboshi, H., Chiba, Y., Kasahara, Y., Takashiba, M., Takaoka, Y., Ohsawa, M., Tajima, Y., Kawashima, I., Tsuji, D., Itoh, K., Sakuraba, H., Jigami, Y. (2007). Production of Recombinant {beta}-Hexosaminidase A, a Potential Enzyme for Replacement Therapy for Tay-Sachs and Sandhoff Diseases, in the Methylotrophic Yeast Ogataea minuta. Appl. Environ. Microbiol. 73: 4805-4812 [Abstract] [Full Text]  
  • Passini, M. A., Lee, E. B., Heuer, G. G., Wolfe, J. H. (2002). Distribution of a Lysosomal Enzyme in the Adult Brain by Axonal Transport and by Cells of the Rostral Migratory Stream. J. Neurosci. 22: 6437-6446 [Abstract] [Full Text]  
  • Brooks, A. I., Stein, C. S., Hughes, S. M., Heth, J., McCray, P. M. Jr., Sauter, S. L., Johnston, J. C., Cory-Slechta, D. A., Federoff, H. J., Davidson, B. L. (2002). From the Cover: Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA 99: 6216-6221 [Abstract] [Full Text]  
  • Passini, M. A., Wolfe, J. H. (2001). Widespread Gene Delivery and Structure-Specific Patterns of Expression in the Brain after Intraventricular Injections of Neonatal Mice with an Adeno-Associated Virus Vector. J. Virol. 75: 12382-12392 [Abstract] [Full Text]  
  • Sondhi, D., Hackett, N. R., Apblett, R. L., Kaminsky, S. M., Pergolizzi, R. G., Crystal, R. G. (2001). Feasibility of Gene Therapy for Late Neuronal Ceroid Lipofuscinosis. Arch Neurol 58: 1793-1798 [Abstract] [Full Text]  
  • Xia, H., Anderson, B., Mao, Q., Davidson, B. L. (2000). Recombinant Human Adenovirus: Targeting to the Human Transferrin Receptor Improves Gene Transfer to Brain Microcapillary Endothelium. J. Virol. 74: 11359-11366 [Abstract] [Full Text]  
  • FAVRE, D., FERRY, N., MOULLIER, P. (2000). Critical Aspects of Viral Vectors for Gene Transfer into the Kidney. J. Am. Soc. Nephrol. 11: S149-S153 [Abstract] [Full Text]  
  • Brooks, A. I., Stein, C. S., Hughes, S. M., Heth, J., McCray, P. M. Jr., Sauter, S. L., Johnston, J. C., Cory-Slechta, D. A., Federoff, H. J., Davidson, B. L. (2002). From the Cover: Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA 99: 6216-6221 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»